A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance

Cancer

Volumn 82, Issue 1, 1998, Pages 70-77

  Yamachika, Takasuke ^a   Nakanishi, Hayao ^a   Inada, Ken Ichi ^a   Tsukamoto, Tetsuya ^a   Kato, Tomoyuki ^a   Fukushima, Masakazu ^b   Inoue, Manami ^a   Tatematsu, Masae ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Colorectal carcinoma; Immunohistochemistry; Prognosis; Thymidylate synthase

Indexed keywords

FLUOROURACIL; MITOMYCIN C; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CARCINOMA; DOSE RESPONSE; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; COLORING AGENTS; CYTOPLASMIC GRANULES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; PROGNOSIS; RECTAL NEOPLASMS; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031941249     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980101)82:1<70::AID-CNCR8>3.0.CO;2-O     Document Type: Article

References (36)

1. Danenberg PV. Thymidylate synthase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977;473:73-92.
2. Santi DV, McHenry CS, Sommer H. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471-80.
3. Danenberg PV, Langenbach RJ, Heidelberger C. Structure of reversible and irreversible complexes of thymidylate synthase and fluoropyrimidine nucleotides. Biochemistry 1974;13:926-33.
4. Volm M, Mattern J. Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas. Anticancer Res 1992;12:2293-6.
5. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
6. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1995;14: 176-82.
7. Sanguedolce R, Brumarescu I, Dardanoni G, Grassadoma A, Vultaggio G, Rausa L. Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study. Anticancer Res 1995;15: 901-6.
8. Washtein WL. Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil. Mol Pharmacol 1984;25:171-7.
9. Clark JL, Berger SL, Mittelman A, Berger FG. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyridine chemotherapy. Cancer Treat Rep 1987;71: 261-5.
10. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-12.
11. Inaba M, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimon A, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996;87:212-20.
12. Spears CP, Antranik AH, Moran RG, Heidelberger FG, Corbett TH. In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil sensitive and resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-6.
13. Okabe H, Tsujimoto H, Fukushima M. Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil. Oncol Rep 1997;4:685-90.
14. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 1981;75:816-21.
15. The Colorectal Cancer Chemotherapy Study Group of Japan. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. Jpn J Clin Oncol 1995;25:91-103.
16. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumours. 4th edition. 2nd revision. Berlin: Springer-Verlag, 1992.
17. Jass JR, Sobin LH. World Health Organization international histological classification of tumors: histological typing of international tumors. 2nd edition. New York: Springer-Verlag, 1989.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-8.
19. Cox DR. Regression models and life tables. J Royal Stat Soc Series B 1972;34:187-220.
20. Dukes CE. The classification of cancer of rectum. J Pathol 1932;35:323.
21. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66: 1960-6.
22. x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993;53:3632-7.
23. a as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 1995;75:2051-6.
24. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reiman HM, Cha SS, Sam WH, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal cancer. Cancer 1991;68:879-88.
25. Silvestrini R, D'Agnano I, Faranda A, Costa A, Zupi G, Cosimelli M, et al. Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience. Br J Cancer 1993;67: 1042-6.
26. Schroy PC 3rd, Brown Shimer S, Kim K, Johnson KA, Murnane MJ, Yang S, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 1995;76:201-9.
27. Span M, Moerkerk PT, De Goeij AF, Arends JW. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 1996;69:241-5.
28. Goh HS, Yao J, Smith DR. P 53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
29. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996;74:216-23.
30. Poller DN, Baxter KJ, Shepherd NA. P 53 and Rb 1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997;75:87-93.
31. Okabe H, Tsujimoto H, Fukushima M. The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase. Jpn J Cancer Chemother 1997;24:705-12.
32. Labow R, Maley GF, Maley F. The effect of methotrexate on enzymes induced following partial hepatectomy. Cancer Res 1969;29:366-72.
33. Che E, Voeller DM, Jones KL, Takechi T, Maley GF, Maley F, et al. Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. Mol Cell Biol 1994;14:207-13.
34. Griswold DP Jr. The potential for murine tumor models in surgical adjuvant chemotherapy. Cancer Chemother Rep 1975;5:187-204.
35. Schabel FM Jr. Concepts for treatment of micrometastases developed in murine systems. AJR Am J Roentgenol 1976; 126:500-11.
36. Schabel FM Jr. Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 1977;40:58-68.